Currently, Angiotensin II receptor blocker or Angiotensin-converting enzyme inhibitor are commonly employed to impede the renin-angiotensin-aldosterone system to slow down the progression of DKD [4].However, conventional renin-angiotensin-aldosterone system inhibitors carry notable side effects, including the risk of hyperkalemia [5]. The gene discussed is REN; the disease is diabetic kidney disease.